Built to Advance
ImmunoShield Therapeutics was founded around the idea that progress in immune-mediated disease requires both scientific precision and practical therapeutic vision
Our Company
The company was created to pursue a more focused path in biotechnology, one that brings together strong biology, translational discipline, and a commitment to solving problems that matter deeply to patients. ImmunoShield is not just developing another therapeutic concept; it is working to refine how immune-targeted treatment can be designed, evaluated, and ultimately delivered.
SOME INSIGHTS
Our Mission & Vision
The Mission
Our mission is to develop precise immune-based therapies that address disease at its biological roots and create better possibilities for patients, providers, and partners.
The Vision
We envision a future in which immune therapies are more selective, more effective, and better matched to the needs of the people they are meant to help.
Leadership Grounded in Science & Execution.
ImmunoShield brings together expertise across biotechnology, immunology, therapeutic development, and company building. We believe breakthrough companies are built by teams that can connect scientific depth with strategic execution.
OUR TEAM
The Minds Behind It All
Jessica Weaver, PhD
CSO
15 years of experience in cell transplantation and biomaterial development, conceived the technology platforms licensed by ImmunoShield Therapeutics.
Matthew Becker, PhD
CEO
Expertise in biomaterials and immune engineering technology platforms helped secure over $2M in non-dilutive funding.
Oren Snir, JD MBA
COO
Business management experience, legal experience in data privacy and technology transactions